Lumos secures US Medicare reimbursement coverage for FebriDx®
17 April 2025
Lumos has announced that it has achieved a series of important reimbursement milestones in the US, with coverage secured for FebriDx®, with two Medicare Administration Contractors (MACs). Effective April 2025, FebriDx, will be reimbursed at US$41.38 per test.
Medicare is an important part of US healthcare reimbursement, comprising 20-24% of the U.S. reimbursement payor mix. There are seven Medicare Administration Contractors (MACs) that support reimbursement processing across the US.
Negotiations are currently underway with the remaining five MACs.
Doug Ward, Managing Director of Lumos Diagnostics commented:
“It is extremely pleasing to achieve some early wins with two of the 7 U.S. Medicare Administration Contractors. This is an important and critical step in building the reimbursement framework to support clinical adoption for FebriDx.
“Manufactured proudly in the United States, FebriDx is not only addressing a critical clinical need in primary care, urgent care, and emergency medicine, but it is also supporting American jobs and innovation in point-of-care diagnostics. Lumos looks forward to the day that FebriDx has broad US reimbursement coverage across both public and private insurers and the team is working to deliver on that objective.”
Click to read the ASX release.
Medicare is an important part of US healthcare reimbursement, comprising 20-24% of the U.S. reimbursement payor mix. There are seven Medicare Administration Contractors (MACs) that support reimbursement processing across the US.
Negotiations are currently underway with the remaining five MACs.
Doug Ward, Managing Director of Lumos Diagnostics commented:
“It is extremely pleasing to achieve some early wins with two of the 7 U.S. Medicare Administration Contractors. This is an important and critical step in building the reimbursement framework to support clinical adoption for FebriDx.
“Manufactured proudly in the United States, FebriDx is not only addressing a critical clinical need in primary care, urgent care, and emergency medicine, but it is also supporting American jobs and innovation in point-of-care diagnostics. Lumos looks forward to the day that FebriDx has broad US reimbursement coverage across both public and private insurers and the team is working to deliver on that objective.”
Click to read the ASX release.
